Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

globenewswire.com
RLMD The article is a neutral announcement about Relmada Therapeutics reporting its second quarter financial results and business progress. It does not contain any information that suggests a positive or negative outlook for the company's stock.

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications

media@relmada.com